ZFGN vs. PYXS, XERS, VTYX, VSTM, AKBA, RAPT, NKTR, AQST, HOWL, and ACIU
Should you be buying Zafgen stock or one of its competitors? The main competitors of Zafgen include Pyxis Oncology (PYXS), Xeris Biopharma (XERS), Ventyx Biosciences (VTYX), Verastem (VSTM), Akebia Therapeutics (AKBA), RAPT Therapeutics (RAPT), Nektar Therapeutics (NKTR), Aquestive Therapeutics (AQST), Werewolf Therapeutics (HOWL), and AC Immune (ACIU). These companies are all part of the "medical" sector.
Pyxis Oncology (NASDAQ:PYXS) and Zafgen (NASDAQ:ZFGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.
In the previous week, Pyxis Oncology had 3 more articles in the media than Zafgen. MarketBeat recorded 3 mentions for Pyxis Oncology and 0 mentions for Zafgen. Zafgen's average media sentiment score of 1.48 beat Pyxis Oncology's score of 0.00 indicating that Pyxis Oncology is being referred to more favorably in the media.
Zafgen received 327 more outperform votes than Pyxis Oncology when rated by MarketBeat users. However, 78.26% of users gave Pyxis Oncology an outperform vote while only 68.59% of users gave Zafgen an outperform vote.
Pyxis Oncology has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, Zafgen has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500.
Pyxis Oncology's return on equity of -51.34% beat Zafgen's return on equity.
Pyxis Oncology presently has a consensus target price of $8.50, indicating a potential upside of 92.74%. Given Zafgen's higher probable upside, equities research analysts clearly believe Pyxis Oncology is more favorable than Zafgen.
Zafgen is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.
39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 70.4% of Zafgen shares are held by institutional investors. 8.4% of Pyxis Oncology shares are held by company insiders. Comparatively, 14.2% of Zafgen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Pyxis Oncology and Zafgen tied by winning 7 of the 14 factors compared between the two stocks.
Get Zafgen News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZFGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZFGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
